<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38059400</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-6551</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>IUBMB life</Title><ISOAbbreviation>IUBMB Life</ISOAbbreviation></Journal><ArticleTitle>Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>241</EndPage><MedlinePgn>228-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/iub.2793</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be over, but its variants continue to emerge, and patients with mild symptoms having long COVID is still under investigation. SARS-CoV-2 infection leading to elevated cytokine levels and suppressed immune responses set off cytokine storm, fatal systemic inflammation, tissue damage, and multi-organ failure. Thus, drug molecules targeting the SARS-CoV-2 virus-specific proteins or capable of suppressing the host inflammatory responses to viral infection would provide an effective antiviral therapy against emerging variants of concern. Evolutionarily conserved papain-like protease (PLpro) and main protease (Mpro) play an indispensable role in the virus life cycle and immune evasion. Direct-acting antivirals targeting both these viral proteases represent an attractive antiviral strategy that is also expected to reduce viral inflammation. The present study has evaluated the antiviral and anti-inflammatory potential of natural triterpenoids: azadirachtin, withanolide_A, and isoginkgetin. These molecules inhibit the Mpro and PLpro proteolytic activities with half-maximal inhibitory concentrations (IC<sub>50</sub>) values ranging from 1.42 to 32.7&#x2009;&#x3bc;M. Isothermal titration calorimetry (ITC) analysis validated the binding of these compounds to Mpro and PLpro. As expected, the two compounds, withanolide_A and azadirachtin, exhibit potent anti-SARS-CoV-2 activity in cell-based assays, with half-maximum effective concentration (EC<sub>50</sub>) values of 21.73 and 31.19&#x2009;&#x3bc;M, respectively. The anti-inflammatory roles of azadirachtin and withanolide_A when assessed using HEK293T cells, were found to significantly reduce the levels of CXCL10, TNF&#x3b1;, IL6, and IL8 cytokines, which are elevated in severe cases of COVID-19. Interestingly, azadirachtin and withanolide_A were also found to rescue the decreased type-I interferon response (IFN-&#x3b1;1). The results of this study clearly highlight the role of triterpenoids as effective antiviral molecules that target SARS-CoV-2-specific enzymes and also host immune pathways involved in virus-mediated inflammation.</AbstractText><CopyrightInformation>&#xa9; 2023 International Union of Biochemistry and Molecular Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nehul</LastName><ForeName>Sanketkumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ankur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panda</LastName><ForeName>Prasan Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine (Division of Infectious diseases), All India Institute of Medical Sciences (AIIMS), Rishikesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Pravindra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Gaurav Kumar</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0002-9996-9422</Identifier><AffiliationInfo><Affiliation>Centre for Animal Disease Research and Diagnosis (CADRAD), Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomar</LastName><ForeName>Shailly</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1730-003X</Identifier><AffiliationInfo><Affiliation>Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IPA/2020/000054</GrantID><Agency>Science and Engineering Research Board, Department of Science &amp; Technology, Government of India</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IUBMB Life</MedlineTA><NlmUniqueID>100888706</NlmUniqueID><ISSNLinking>1521-6543</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C000706209">3C-like proteinase, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.2</RegistryNumber><NameOfSubstance UI="D000086882">Coronavirus Papain-Like Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="N">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086882" MajorTopicYN="N">Coronavirus Papain-Like Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">PLpro</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">triterpenoids</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38059400</ArticleId><ArticleId IdType="doi">10.1002/iub.2793</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hafezi B, Chan L, Knapp JP, Karimi N, Alizadeh K, et al. Cytokine storm syndrome in SARS&#x2010;CoV&#x2010;2 infections: a functional role of mast cells. Cells. 2021;10:1761&#x2013;1765.</Citation></Reference><Reference><Citation>Hu B, Huang S, Yin L. The cytokine storm and COVID&#x2010;19. J Med Virol. 2021;93:250&#x2013;256.</Citation></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID&#x2010;19. Signal Transduct Target Ther. 2021;6:255.</Citation></Reference><Reference><Citation>Costela&#x2010;Ruiz VJ, Illescas&#x2010;Montes R, Puerta&#x2010;Puerta JM, Ruiz C, Melguizo&#x2010;Rodr&#xed;guez L. SARS&#x2010;CoV&#x2010;2 infection: the role of cytokines in COVID&#x2010;19 disease. Cytokine Growth Factor Rev. 2020;54:62&#x2013;75.</Citation></Reference><Reference><Citation>Neufeldt CJ, Cerikan B, Cortese M, Frankish J, Lee J&#x2010;Y, Plociennikowska A, et al. SARS&#x2010;CoV&#x2010;2 infection induces a pro&#x2010;inflammatory cytokine response through cGAS&#x2010;STING and NF&#x2010;&#x3ba;B. Commun Biol. 2022;5:45.</Citation></Reference><Reference><Citation>Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS&#x2010;CoV&#x2010;2 triggers inflammatory responses and cell death through caspase&#x2010;8 activation. Signal Transduct Target Ther. 2020;5:235.</Citation></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID&#x2010;19 patients. Science. 2020;369:718&#x2013;724.</Citation></Reference><Reference><Citation>Bastard P, Zhang Q, Zhang S&#x2010;Y, Jouanguy E, Casanova J&#x2010;L. Type I interferons and SARS&#x2010;CoV&#x2010;2: from cells to organisms. Curr Opin Immunol. 2022;74:172&#x2013;182.</Citation></Reference><Reference><Citation>Kindler E, Thiel V. SARS&#x2010;CoV and IFN: too little, too late. Cell Host Microbe. 2016;19:139&#x2013;141.</Citation></Reference><Reference><Citation>Kim Y&#x2010;M, Shin E&#x2010;C. Type I and III interferon responses in SARS&#x2010;CoV&#x2010;2 infection. Exp Mol Med. 2021;53:750&#x2013;760.</Citation></Reference><Reference><Citation>Sun X, Wang T, Cai D, Hu Z, Chen J, et al. Cytokine storm intervention in the early stages of COVID&#x2010;19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38&#x2013;42.</Citation></Reference><Reference><Citation>Zhou Y&#x2010;W, Xie Y, Tang L&#x2010;S, Pu D, Zhu Y&#x2010;J, Liu JY, et al. Therapeutic targets and interventional strategies in COVID&#x2010;19: mechanisms and clinical studies. Signal Transduct Target Ther. 2021;6:317.</Citation></Reference><Reference><Citation>V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS&#x2010;CoV&#x2010;2. Nat Rev Microbiol. 2021;19:155&#x2013;170.</Citation></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS&#x2010;CoV&#x2010;2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468.</Citation></Reference><Reference><Citation>Dubey A, Choudhary S, Kumar P, Tomar S. Emerging SARS&#x2010;CoV&#x2010;2 variants: genetic variability and clinical implications. Curr Microbiol. 2021;79:20.</Citation></Reference><Reference><Citation>Rani R, Long S, Pareek A, Dhaka P, Singh A, Kumar P, et al. Multi&#x2010;target direct&#x2010;acting SARS&#x2010;CoV&#x2010;2 antivirals against the nucleotide&#x2010;binding pockets of virus&#x2010;specific proteins. Virology. 2022;577:1&#x2013;15.</Citation></Reference><Reference><Citation>Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus Main proteinase (3CLpro) structure: basis for design of anti&#x2010;SARS drugs. Science. 2003;300:1763&#x2013;1767.</Citation></Reference><Reference><Citation>Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS&#x2010;CoV&#x2010;2 main protease provides a basis for design of improved &#x3b1;&#x2010;ketoamide inhibitors. Science. 2020;368:409&#x2013;412.</Citation></Reference><Reference><Citation>G&#xfc;nther S, Reinke PYA, Fern&#xe1;ndez&#x2010;Garc&#xed;a Y, Lieske J, Lane TJ, Ginn HM, et al. X&#x2010;ray screening identifies active site and allosteric inhibitors of SARS&#x2010;CoV&#x2010;2 main protease. Science. 2021;372:642&#x2013;646.</Citation></Reference><Reference><Citation>Rani R, Singh A, Pareek A, Tomar S. In silico guided drug repurposing to combat SARS&#x2010;CoV&#x2010;2 by targeting Mpro, the key virus specific protease. bioRxiv. 2020.</Citation></Reference><Reference><Citation>Wenhao D, Bing Z, Xia&#x2010;Ming J, Haixia S, Jian L, et al. Structure&#x2010;based design of antiviral drug candidates targeting the SARS&#x2010;CoV&#x2010;2 main protease. Science. 2020;368:1331&#x2013;1335.</Citation></Reference><Reference><Citation>Yongzhen, L., Chao, Q., Youliang, R., et al. (2021) SARS&#x2010;CoV&#x2010;2 Nsp5 demonstrates two distinct mechanisms targeting RIG&#x2010;I and MAVS to evade the innate immune response. MBio 12, e0233521.</Citation></Reference><Reference><Citation>Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW, Bernardini JP, et al. Mechanism and inhibition of the papain&#x2010;like protease, PLpro, of SARS&#x2010;CoV&#x2010;2. EMBO J. 2020;39:e106275.</Citation></Reference><Reference><Citation>Fu Z, Huang B, Tang J, Liu S, Liu M, Ye Y, et al. The complex structure of GRL0617 and SARS&#x2010;CoV&#x2010;2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun. 2021;12:488.</Citation></Reference><Reference><Citation>McClain CB, Vabret N. SARS&#x2010;CoV&#x2010;2: the many pros of targeting PLpro. Signal Transduct Target Ther. 2020;5:223.</Citation></Reference><Reference><Citation>Zong Z, Zhang Z, Wu L, Zhang L, Zhou F. The functional deubiquitinating enzymes in control of innate antiviral immunity. Adv Sci. 2021;8:2002484.</Citation></Reference><Reference><Citation>Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain&#x2010;like protease regulates SARS&#x2010;CoV&#x2010;2 viral spread and innate immunity. Nature. 2020;587:657&#x2013;662.</Citation></Reference><Reference><Citation>Osipiuk J, Azizi S&#x2010;A, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, et al. Structure of papain&#x2010;like protease from SARS&#x2010;CoV&#x2010;2 and its complexes with non&#x2010;covalent inhibitors. Nat Commun. 2021;12:743.</Citation></Reference><Reference><Citation>Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78:431&#x2013;441.</Citation></Reference><Reference><Citation>Perumal Samy R, Gopalakrishnakone P. Therapeutic potential of plants as anti&#x2010;microbials for drug discovery. Evid Based Complement Alternat Med. 2010;7:260483.</Citation></Reference><Reference><Citation>Subramani P. Herbal drug discovery: challenges and perspectives. Curr Pharmacogenom Pers Med. 2018;16:63&#x2013;68.</Citation></Reference><Reference><Citation>Zeenat Fahmeeda, R. M. S. A. W. and A. I. (2018) Therapeutic, phytochemistry and pharmacology of Azadirachta indica: a review. Int J Unani Integr Med 2, 20&#x2013;28.</Citation></Reference><Reference><Citation>Rayees S, Malik F. Withania somnifera: from traditional use to evidence based medicinal prominence. Science of ashwagandha: preventive and therapeutic potentials. Springer International Publishing, Cham, Switzerland; 2017. p. 81&#x2013;103.</Citation></Reference><Reference><Citation>Kaur R, Neetu, Mudgal R, Jose J, Kumar P, et al. Glycan&#x2010;dependent chikungunya viral infection divulged by antiviral activity of NAG specific chi&#x2010;like lectin. Virology. 2019;526:91&#x2013;98.</Citation></Reference><Reference><Citation>Choudhary S, Neetu N, Singh VA, Kumar P, Chaudhary M, Tomar S. Chikungunya virus titration, detection and diagnosis using N&#x2010;acetylglucosamine (GlcNAc) specific lectin based virus capture assay. Virus Res. 2021;302:198493.</Citation></Reference><Reference><Citation>Cohen MM. Tulsi&#x2014;Ocimum sanctum: a herb for all reasons. J Ayurveda Integr Med. 2014;5:251&#x2013;259.</Citation></Reference><Reference><Citation>Tiwari V, Darmani NA, Yue BYJT, Shukla D. In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type&#x2010;1 infection. Phytother Res. 2010;24:1132&#x2013;1140.</Citation></Reference><Reference><Citation>Parida MM, Upadhyay C, Pandya G, Jana AM. Inhibitory potential of neem (Azadirachta indica Juss) leaves on dengue virus type&#x2010;2 replication. J Ethnopharmacol. 2002;79:273&#x2013;278.</Citation></Reference><Reference><Citation>Verma SK, Kumar A. Therapeutic uses of Withania somnifera (Ashwagandha) with a note on withanolides and its pharmacological actions. Asian J Pharm Clin Res. 2011;4:1&#x2013;4.</Citation></Reference><Reference><Citation>Paul S, Chakraborty S, Anand U, Dey S, Nandy S, Ghorai M, et al. Withania somnifera (L.) Dunal (Ashwagandha): a comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed Pharmacother. 2021;143:112175.</Citation></Reference><Reference><Citation>Kashyap VK, Dhasmana A, Yallapu MM, Chauhan SC, Jaggi M. Withania somnifera as a potential future drug molecule for COVID&#x2010;19. Future Drug Discov. 2020;2:FDD50.</Citation></Reference><Reference><Citation>Haruyama T, Nagata K. Anti&#x2010;influenza virus activity of Ginkgo biloba leaf extracts. J Nat Med. 2013;67:636&#x2013;642.</Citation></Reference><Reference><Citation>Jessica, T., Mena, A.&#x2010;N., Armin, F., T, S. M., Stephanie, P., et al. (2019) Isoginkgetin, a natural Biflavonoid proteasome inhibitor, sensitizes cancer cells to apoptosis via disruption of lysosomal homeostasis and impaired protein clearance. Mol Cell Biol 39, e0048918.</Citation></Reference><Reference><Citation>Darrigrand R, Pierson A, Rouillon M, Renko D, Boulpicante M, Bouyssi&#xe9; D, et al. Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens. Commun Biol. 2021;4:269.</Citation></Reference><Reference><Citation>Sharma M, Mahto JK, Dhaka P, Neetu N, Tomar S, Kumar P. MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS&#x2010;CoV&#x2010;2. J Biomol Struct Dyn. 2022;40:12048&#x2013;12061.</Citation></Reference><Reference><Citation>Kumar KA, Sharma M, Dalal V, Singh V, Tomar S, Kumar P. Multifunctional inhibitors of SARS&#x2010;CoV&#x2010;2 by MM/PBSA, essential dynamics, and molecular dynamic investigations. J Mol Graph Model. 2021;107:107969.</Citation></Reference><Reference><Citation>Dhanjal JK, Kumar V, Garg S, Subramani C, Agarwal S, Wang J, et al. Molecular mechanism of anti&#x2010;SARS&#x2010;CoV2 activity of ashwagandha&#x2010;derived withanolides. Int J Biol Macromol. 2021;184:297&#x2013;312.</Citation></Reference><Reference><Citation>Patil VS, Hupparage VB, Malgi AP, Deshpande SH, Patil SA, Mallapur SP. Dual inhibition of COVID&#x2010;19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera. Chin Herbal Med. 2021;13:359&#x2013;369.</Citation></Reference><Reference><Citation>Khanal P, Chikhale R, Dey YN, Pasha I, Chand S, Gurav N, et al. Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID&#x2010;19. J Biomol Struct Dyn. 2022;40:5295&#x2013;5308.</Citation></Reference><Reference><Citation>Chakraborty S, Mallick D, Goswami M, Guengerich FP, Chakrabarty A, Chowdhury G. The natural products withaferin a and Withanone from the medicinal herb Withania somnifera are covalent inhibitors of the SARS&#x2010;CoV&#x2010;2 Main protease. J Nat Prod. 2022;85:2340&#x2013;2350.</Citation></Reference><Reference><Citation>Dhaka P, Singh A, Choudhary S, Peddinti RK, Kumar P, Sharma GK, et al. Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N&#x2010;terminal domain of SARS&#x2010;CoV&#x2010;2. Archives of Biochemistry and Biophysics. 2023;750:109820&#x2013;109830.</Citation></Reference><Reference><Citation>Choudhary S, Nehul S, Kumar KA, Sharma S, Rani R, et al. (2022) Crystal structure and activity profiling of deubiquitinating inhibitors&#x2010;bound to SARS&#x2010;CoV&#x2010;2 papain like protease revealed new allosteric sites for antiviral therapies. bioRxiv, 2022.11.11.516107.</Citation></Reference><Reference><Citation>Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID&#x2010;19: addressing a pharmacological challenge by targeting pathways triggered by SARS&#x2010;CoV&#x2010;2. Signal Transduct Target Ther. 2020;5:84.</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid&#x2010;19 &#x2014; final report. N Engl J Med. 2020;383:1813&#x2013;1826.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x2010;nCoV) in vitro. Cell Res. 2020;30:269&#x2013;271.</Citation></Reference><Reference><Citation>Wang Y, Zhang D, Du G, Du R, Zhao J, et al. Remdesivir in adults with severe COVID&#x2010;19: a randomised, double&#x2010;blind, placebo&#x2010;controlled, multicentre trial. Lancet. 2020;395:1569&#x2013;1578.</Citation></Reference><Reference><Citation>Kabinger F, Stiller C, Schmitzov&#xe1; J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir&#x2010;induced SARS&#x2010;CoV&#x2010;2 mutagenesis. Nat Struct Mol Biol. 2021;28:740&#x2013;746.</Citation></Reference><Reference><Citation>Singh M, de Wit E. Antiviral agents for the treatment of COVID&#x2010;19: progress and challenges. Cell Rep Med. 2022;3:100549.</Citation></Reference><Reference><Citation>Burki TK. The role of antiviral treatment in the COVID&#x2010;19 pandemic. Lancet Respir Med. 2022;10:e18.</Citation></Reference><Reference><Citation>Chitalia VC, Munawar AH. A painful lesson from the COVID&#x2010;19 pandemic: the need for broad&#x2010;spectrum, host&#x2010;directed antivirals. J Transl Med. 2020;18:390.</Citation></Reference><Reference><Citation>Maarifi G, Martin M&#x2010;F, Zebboudj A, Boulay A, Nouaux P, Fernandez J, et al. Identifying enhancers of innate immune signaling as broad&#x2010;spectrum antivirals active against emerging viruses. Cell Chem Biol. 2022;29:1113&#x2013;1125.e6.</Citation></Reference><Reference><Citation>Kiira R, Scott P, Jun T, Katrina S, Melissa C, et al. A noncovalent class of papain&#x2010;like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci. 2008;105:16119&#x2013;16124.</Citation></Reference><Reference><Citation>Wioletta R, Zongyang L, Mikolaj Z, Stephanie P, Digant N, et al. Activity profiling and crystal structures of inhibitor&#x2010;bound SARS&#x2010;CoV&#x2010;2 papain&#x2010;like protease: a framework for anti&#x2013;COVID&#x2010;19 drug design. Sci Adv. 2021;6:eabd4596.</Citation></Reference><Reference><Citation>Wu Y, Ma L, Zhuang Z, Cai S, Zhao Z, Zhou L, et al. Main protease of SARS&#x2010;CoV&#x2010;2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct Target Ther. 2020;5:221.</Citation></Reference><Reference><Citation>Sharma V, Kaushik S, Pandit P, Dhull D, Yadav JP, Kaushik S. Green synthesis of silver nanoparticles from medicinal plants and evaluation of their antiviral potential against chikungunya virus. Appl Microbiol Biotechnol. 2019;103:881&#x2013;891.</Citation></Reference><Reference><Citation>Hemdan BA, Mostafa A, Elbatanony MM, El&#x2010;Feky AM, Paunova&#x2010;Krasteva T, et al. Bioactive Azadirachta indica and Melia azedarach leaves extracts with anti&#x2010;SARS&#x2010;CoV&#x2010;2 and antibacterial activities. PloS One. 2023;18:e0282729.</Citation></Reference><Reference><Citation>Zhang X, Chen L, Hu C, Fast D, Zhang L, Yang B, et al. Curcumin attenuates poly(I:C)&#x2010;induced immune and inflammatory responses in mouse macrophages by inhibiting TLR3/TBK1/IFNB cascade. J Funct Foods. 2022;89:104949.</Citation></Reference><Reference><Citation>Sarkar L, Oko L, Gupta S, Bubak AN, Das B, et al. Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict &#x3b2;&#x2010;coronaviral infection and replication. Virology. 2022;569:13&#x2013;28.</Citation></Reference><Reference><Citation>Gupta M, Kaur G. Aqueous extract from the Withania somnifera leaves as a potential anti&#x2010;neuroinflammatory agent: a mechanistic study. J Neuroinflammation. 2016;13:193.</Citation></Reference><Reference><Citation>Nayak D, Ashe S, Rauta PR, Kumari M, Nayak B. Bark extract mediated green synthesis of silver nanoparticles: evaluation of antimicrobial activity and antiproliferative response against osteosarcoma. Mater Sci Eng C. 2016;58:44&#x2013;52.</Citation></Reference><Reference><Citation>Behl T, Kumar K, Brisc C, Rus M, Nistor&#x2010;Cseppento DC, Bustea C, et al. Exploring the multifocal role of phytochemicals as immunomodulators. Biomed Pharmacother. 2021;133:110959.</Citation></Reference><Reference><Citation>Puhl AC, Gomes GF, Damasceno S, Fritch EJ, Levi JA, Johnson NJ, et al. Vandetanib blocks the cytokine storm in SARS&#x2010;CoV&#x2010;2&#x2010;infected mice. ACS Omega. 2022;7:31935&#x2013;31944.</Citation></Reference><Reference><Citation>Dobosh B, Zandi K, Giraldo DM, Goh SL, Musall K, Aldeco M, et al. Baricitinib attenuates the proinflammatory phase of COVID&#x2010;19 driven by lung&#x2010;infiltrating monocytes. Cell Rep. 2022;39:110945.</Citation></Reference><Reference><Citation>Gao X, Chan PKS, Lui GCY, Hui DSC, Chu IM&#x2010;T, Sun X, et al. Interleukin&#x2010;38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death Dis. 2021;12:53.</Citation></Reference><Reference><Citation>Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, et al. Famotidine inhibits toll&#x2010;like receptor 3&#x2010;mediated inflammatory signaling in SARS&#x2010;CoV&#x2010;2 infection. J Biol Chem. 2021;297:100925.</Citation></Reference><Reference><Citation>Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain&#x2010;like protease inhibits the type I interferon signaling pathway through interaction with the STING&#x2010;TRAF3&#x2010;TBK1 complex. Protein Cell. 2014;5:369&#x2013;381.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>